Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2021-08-23 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
2021年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2021 Half-Year Special Report on the Deposit and Use of Raised Funds" by Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the status of funds raised through a non-public stock issuance, including amounts raised, usage, balances, and compliance with regulatory requirements. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange concerning the management and disclosure of raised funds. It includes detailed financial figures about the raised funds, their allocation, and usage during the first half of 2021. The document is a specialized report focusing on the management and use of capital raised by the company, not a full annual or interim financial report, nor an announcement or presentation. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (5489 characters) and content confirm it is a substantive report, not merely an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2021-08-23 Chinese
关于终止“nanatinostat”独家许可使用权协议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the termination of an exclusive license agreement for the drug 'nanatinostat'. It details the background of the agreement, the reasons for termination, the terms of the termination agreement, and the impact on the company. The document includes board meeting resolutions and legal procedural information. It is a formal disclosure of a corporate transaction and contract termination, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. The document is a regulatory announcement about a corporate transaction and contract termination, fitting best under Regulatory Filings (RNS). The document length is 2748 characters, which is relatively short and consistent with an announcement rather than a full report.
2021-08-23 Chinese
2021年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2021 年半年度报告摘要" which translates to "2021 Half-Year Report Summary". It contains detailed financial data for the half-year period, including revenue, net profit, cash flow, earnings per share, and asset information. It also discusses business operations, R&D progress, clinical trials, product pipeline, and capital market activities during the reporting period. The length is substantial (9542 characters), and it includes substantive financial data and management discussion. This matches the characteristics of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and analysis. It is not merely an announcement or summary without data, nor is it a full annual report (10-K). Therefore, the correct classification is IR. H1 2021
2021-08-23 Chinese
第五届监事会第十五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Shenzhen Salubris Pharmaceuticals Co., Ltd. It reports the approval of the company's 2021 semi-annual report and a special report on the use of raised funds. The document includes statements about the legality and accuracy of the reports but does not contain the actual financial data or the full semi-annual report itself. It also references where the full reports can be found (on cninfo.com.cn and other media). The document length is short (1197 characters) and serves as an official announcement of the Supervisory Board's meeting resolutions rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a formal announcement of meeting resolutions and report approvals without containing the full report or detailed financial data.
2021-08-23 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion statement by the independent directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the company's half-year fundraising fund storage and usage, external guarantees, and related party fund occupation as of June 30, 2021. It references compliance with relevant laws and regulations and provides assurance on the company's financial and operational practices related to fundraising and guarantees. The document is relatively short (2218 characters) and does not contain detailed financial statements or comprehensive financial analysis. It is a specialized independent opinion report rather than a full interim or annual report. This type of document is best classified as a Regulatory Filing (RNS) because it is a compliance-related statement and does not fit the definitions of other specific report types such as Annual Report, Interim Report, or Audit Report.
2021-08-23 Chinese
2021年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳信立泰药业股份有限公司 2021 年半年度财务报告" which translates to "Shenzhen Salubris Pharmaceuticals Co., Ltd. 2021 Semi-Annual Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2021. The report explicitly states it is a half-year (semi-annual) financial report and includes comprehensive financial data and analysis for the period. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-23 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.